Kabra Drugs has given a return of 4900 percent to investors in the last 7 years.
The ongoing ups and downs in the stock market have emphasized the importance of identifying those stocks which have the potential to generate good earnings. In many cases, stock-specific investments have given much higher returns than the benchmark index. However, with the potential for huge profits comes increased risk, making detailed research, careful portfolio allocation and a disciplined long-term investment strategy essential aspects of investing.
Here, we will talk about one such stock, Kabra Drugs. This penny stock has consistently outperformed the broader market and given multibagger returns to its investors. The share price of Kabra Drugs, which was once Rs 65 in February 2019, is now trading at Rs 32 on BSE. If you think of it this way, an investment of Rs 1 lakh in the stock six years ago and held over time would have given it a value of Rs 50 lakh in seven years.
kabra drugs share price
Kabra Drugs shares have proven to be a wealth multiplier for long-term investors by giving multibagger returns of 4960 percent in the last seven years. This multibagger stock has increased by 589 percent in five years and about 514 percent in three years. Even in the short term, the stock has managed to impress investors despite weak market sentiment. This stock has given 209 percent return in one year, whereas during this period BSE Sensex has seen an increase of only 10 percent. Moreover, the multibagger penny stock has gained more than 65 per cent in six months and 17 per cent in one month.
Recent Business Updates of Kabra Drugs
With several strategic initiatives first approved in January 2026, its expansion into high-growth sectors and tremendous investor enthusiasm have pushed the stock prices further higher. On Tuesday, the company reported a 578 per cent year-on-year (YoY) increase in net profit at Rs 2.56 crore for the December quarter of FY26, compared to a loss of Rs 53.69 lakh in the same period last year.
As per PTI report, for the December quarter, Kabra Drugs posted revenue of Rs 30.42 crore, which shows a strong growth of 53.9 per cent from Rs 19.76 crore reported in the September 2025 quarter, and a big change from zero revenue reported in the December 2024 quarter.
Additionally, Kabra Drugs entered into an agreement with MR Franchise to onboard 200 channel partners across the country, which will improve its distribution network and increase its market reach. On January 1, the company board has approved the acquisition of Wassman Automotive Pvt Ltd, change of company name, expansion and diversification of distribution network and change in main objective (MOA).
